Literature DB >> 8236361

Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A.

A M Gardier1, D Mathé, X Guédeney, J Barré, C Benvenutti, N Navarro, L Vernillet, D Loisance, J P Cachera, B Jacotot.   

Abstract

The present study attempted to characterize the distribution of cyclosporin A (CsA) among the lipoprotein fractions, very-low-, intermediate-, low-, and high-density (VLDL, IDL, LDL, and HDL, respectively) in the plasma of patients awaiting heart transplantation and the influence of plasma lipid constituents on the pharmacokinetics of CsA. Major fractions of a therapeutic concentration of CsA were found in HDL and in LDL. In addition, plasma lipid concentrations (total cholesterol, triglycerides, phospholipids, VLDL-cholesterol--TC, TG, PL, VLDLc, respectively) are positively correlated with the CsA distribution within the LDL fraction, and negatively correlated with the CsA distribution within the HDL fraction. Thus, the percentage of CsA in each type of lipoproteins was shown to vary with the lipid levels among individuals. A significant negative correlation was found between apparent distribution volume at steady state (Vss) in plasma and TC, PL, and LDLc and between the area under the curve measured in blood (AUCB) for whole blood and PL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8236361     DOI: 10.1097/00007691-199308000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

Review 1.  Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A.

Authors:  Kishor M Wasan; Manisha Ramaswamy; Mona Kwong; Kathy D Boulanger
Journal:  AAPS PharmSci       Date:  2002

2.  Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Authors:  K M Wasan; R Subramanian; J W Chou; M Ramaswamy; P H Pritchard
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

3.  A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine.

Authors:  K M Wasan; S M Cassidy; M Ramaswamy; A Kennedy; F W Strobel; S P Ng; T Y Lee
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

4.  Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.

Authors:  M Ramaswamy; K D Peteherych; A L Kennedy; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.

Authors:  K M Wasan; P H Pritchard; M Ramaswamy; W Wong; E M Donnachie; L J Brunner
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

6.  Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function.

Authors:  Hamidreza Montazeri Aliabadi; Tara J Spencer; Parvin Mahdipoor; Afsaneh Lavasanifar; Dion R Brocks
Journal:  AAPS J       Date:  2006-10-27       Impact factor: 4.009

Review 7.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.

Authors:  K M Wasan; A L Kennedy; S M Cassidy; M Ramaswamy; L Holtorf; J W Chou; P H Pritchard
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.

Authors:  Kishor M Wasan; Olena Sivak; Richard A Cote; Aaron I MacInnes; Kathy D Boulanger; Melvyn Lynn; William J Christ; Lynn D Hawkins; Daniel P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Cyclosporine binds to the neutral lipid and potentially other binding sites of lipid transfer protein I.

Authors:  Mona Kwong; Kishor M Wasan
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.